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INTRODUCTION
Mesenchymal stem cells (MSCs) have been successfully iso-
lated from healthy brains,1 and were first isolated from human 
glioma specimens by Lang, et al.2 and Hossain, et al.3 Tumor 
mesenchymal stem-like cells (tMSLCs) have also been isolated 
from some brain tumors.4-7 These studies suggested that 
tMSLCs enhance glioma progression by influencing the stro-
ma of the glioma microenvironment.3,8-11 Moreover, a recent 
study found that the success of tMSLC isolation is a negative 
prognostic factor of the overall survival of patients with grade 
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Purpose: A critical indicator of the overall survival of patients with high-grade glioma is the successful isolation of tumor mesen-
chymal stem-like cells (tMSLCs), which play important roles in glioma progression. However, attempts to isolate tMSLCs from 
surgical specimens have not always been successful, and the reasons for this remain unclear. Considering that the amount of sur-
gical high-grade glioma specimens varies, we hypothesized that larger surgical specimens would be better for tMSLC isolation.
Materials and Methods: We assessed 51 fresh, high-grade glioma specimens and divided them into two groups according to the 
success or failure of tMSLC isolation. The success of tMSLC isolation was confirmed by plastic adherence, presenting antigens, 
tri-lineage differentiation, and non-tumorigenicity. Differences in characteristics between the two groups were tested using inde-
pendent two sample t-tests, chi-square tests, or Kaplan-Meier survival analysis.  
Results: The mean specimen weights of the groups differed from each other (tMSLC-negative group: 469.9±341.9 mg, tMSLC posi-
tive group: 546.7±618.9 mg), but the difference was not statistically significant. The optimal cut-off value of specimen weight was 
180 mg, and the area under the curve value was 0.599.
Conclusion: Our results suggested a minimum criterion for specimen collection, and found that the specimen amount was not 
deeply related to tMSLC detection. Collectively, our findings imply that the ability to isolate tMSLCs is determined by factors oth-
er than the specimen amount.
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IV gliomas, as classified based on the World Health Organiza-
tion (WHO) criteria.12 Notably, however, a previous study by 
our laboratory found that when tMSLCs were cultured in vitro 
from high-grade glioma (WHO grade III, IV) specimens under 
appropriate conditions, not all tMSLC isolations were success-
ful.5 Therefore, understanding the factors that determine the 
success or failure of tMSLC isolation is important for ensuring 
proper sampling.
Previously, we performed an analysis of the success or fail-
ure of tumor sphere isolation according to specimen weight.13 
We hypothesized that heavier specimens would yield higher 
tumor sphere isolation success rates; however, our data did 
not support this hypothesis, as no relationship was identified 
between the specimen amount and the tumor sphere isola-
tion rate. Moreover, whether the specimen amount is associat-
ed with the rate of tMSLC isolation remains unclear. Since the 
amount of surgical specimens varies, it is possible that the tMSLC 
isolation rate is higher for heavier surgical specimens. Although 
several prior studies reported the success rate of isolating MSCs 
and tMSLCs in high-grade gliomas and other tumors,1,3-7,14-18 the 
optimal specimen weight for the successful isolation of tMSLCs 
has not yet been established.
Therefore, the present study aimed to determine the optimal 
weight of surgical specimens for maximizing the isolation rate of 
tMSLCs. Specifically, we tested the hypothesis that heavier spec-
imens would have a higher success rate for tMSLC isolation. 
MATERIALS AND METHODS
Patient information
Fifty-one patients with high-grade glioma (WHO grade III, IV 
gliomas) who underwent resection surgery at our institution 
(Severance Hospital, Yonsei University College of Medicine) 
from October 2014 to December 2015 were enrolled in this 
study (Table 1). Patients were included if they had histological-
Table 1. Demographic and Clinical Characteristics of Patients with High-Grade Glioma
Characteristics tMSLC-negative (n=23) tMSLC-positive (n=28) p value
Sex 0.793
Male 14 (60.9) 16 (57.1)
Female 9 (39.1) 12 (42.9)
Age (yr) 50.9±17.3 58.5±12.2 0.083
Pathologic diagnosis 0.327
Anaplastic astrocytoma, IDH-mutant 1 (4.3)  0 (0.0)
Anaplastic astrocytoma, IDH-wildtype 5 (21.7) 3 (10.7)
Anaplastic oligodendroglioma, IDH-mutant, and 1p19q-codeleted 2 (8.7) 1 (3.6)
Glioblastoma, IDH-wildtype 15 (65.2) 24 (85.7)
Origin 0.132
Primary 18 (78.3) 26 (92.9)
Recurrent 5 (21.7) 2 (7.1)
Molecular markers
IDH-1 0.211
Negative 20 (87.0) 27 (96.4)
Positive 3 (13.0) 1 (3.6)
EGFR 0.254
Mutant by FISH 12 (52.2) 19 (67.9)
Wildtype 11 (47.8) 9 (32.1)
p53 0.785
Mutant by immunohistochemistry 18 (78.3) 21 (75.0)
Wildtype 5 (21.7) 7 (25.0)
MGMT 0.254
Methylation 11 (47.8) 9 (32.1)
Unmethylation 12 (52.2) 19 (67.9)
1p19q codeletion >0.999
No 18 (78.3) 23 (82.1)
Yes 5 (21.7) 5 (17.9)
Ki-67 (%) 20.9±12.4 22.2±19.3 0.765
tMSLC, tumor mesenchymal stem-like cell; IDH, isocitrate dehydrogenase; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; 
MGMT, O-6-methylguanine-DNA methyltransferase.
Data are presented as n (%) or mean±standard deviation.
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ly confirmed WHO grade III, IV gliomas according to the 2016 
WHO criteria.19-21 Patients’ demographic characteristics, sur-
vival time, the extent of resection, specimen weight, and results 
of tMSLC isolation were investigated and analyzed statistically. 
Molecular markers in the surgical specimens were examined 
by neuropathologists as follows: isocitrate dehydrogenase-1 
(IDH-1) mutation was assessed by or immunohistochemistry 
using the R132H mouse monoclonal antibody (clone H09 L, 
Dianova; 1:80 dilution). O-6-methylguanine-DNA methyl-
transferase (MGMT) promoter methylation was evaluated by 
polymerase chain reaction. The loss of heterozygosity at chro-
mosomes 1p and 19q and the epidermal growth factor recep-
tor (EGFR) mutation status were assessed by fluorescence in 
situ hybridization, and the mutational status of the tumor-
suppressor protein p53 was characterized by immunohisto-
chemistry.22,23 All patients provided written informed consent, 
and permission for specimen sampling and evaluation was 
obtained from the Institutional Review Boards of our institu-
tion (4-2012-0212, 4-2014-0649), as specified in the Declara-
tion of Helsinki.
Surgical specimen sampling
Fifty-one tumor specimens from 51 patients were freshly ob-
tained from 5-aminolevulinic acid fluorescent-guided surgery. 
After obtaining the tumor tissue, half or a third of the tissue was 
removed and sampled for tMSLC culture. The areas that were 
stained brightly by fluorescence were excised with the help of a 
microscope so that high fluorescence uptake specimens could 
be included. Every fresh specimen was placed into a sterile 
centrifuge tube (SPL Life Sciences Co., Pocheon, Korea) on ice 
and weighed on the same electronic precision balance (Sartori-
us TE4101-L; Sartorius Weighing Technology GmbH, Göttin-
gen, Germany) within 1 h.24-31
Single-cell isolation and culture of tMSLCs
Fresh specimen samples were minced with a scalpel in mini-
mal essential medium-α (MEMα; Mediatech, Herndon, VA, 
USA) and passed through a series of 100-μm nylon mesh cell 
strainers (BD Falcon, Franklin Lakes, NJ, USA). The resulting 
cell suspensions were combined and washed twice in serum-
free MEMα, and then cultured in complete MSC medium con-
sisting of MEMα, 10% fetal bovine serum (Gibco, Invitrogen, 
Carlsbad, CA, USA), 2-mM L-glutamine (Mediatech), and 1X 
antibiotic-antimycotic solution (Invitrogen, Carlsbad, CA, USA). 
After 24 h, nonadherent cells were removed by washing twice 
with phosphate-buffered saline (Mediatech) and cultured un-
til they reached confluence. Thereafter, cells were trypsinized 
(0.25% trypsin with 0.1% ethylenediaminetetraacetic acid) 
and sub-cultured at a density of 5000 cells/cm2. The obtained 
isolated cells were assessed for several mesenchymal features, 
including adhesion to plastic, tri-lineage differentiation, and the 
presence of typical MSC surface markers (positive for CD105, 
CD90, and CD72; negative for CD45, CD31, and NG2).
Statistical analysis
The patients’ demographic characteristics and surgical speci-
men weights were statistically evaluated using independent 
two sample t-tests for continuous variables and chi-squared 
tests for categorical variables. Area under the curve (AUC) val-
ues and the Youden index, in conjunction with receiver-oper-
ating characteristic analyses, were used to determine the opti-
mal cut-off weight of surgical specimens for isolating tMSLCs 
that maximized sensitivity and specificity. Survival curves for 
the two groups were calculated using the Kaplan-Meier meth-
od. All statistical analyses were performed using SPSS version 
21.0 (IBM Corp., Armonk, NY, USA), and statistical significance 
was set at p<0.05. Values are presented as the means±standard 
deviation or count (%).
RESULTS
Characteristics of the patients and surgical specimens
Among the 51 collected specimens, 30 were from male and 21 
were from female, and the patients’ age ranged from 21 to 77 
years. Of the 51 specimens, 44 were primary tumors, none was 
secondary, and 7 were recurrent types. Pathological diagnoses 
included glioblastoma, IDH-wildtype (n=39); anaplastic astro-
cytoma, IDH-mutant (n=1); anaplastic astrocytoma, IDH-wild-
type (n=8); and anaplastic oligodendroglioma, IDH-mutant and 
1p19q-codeleted (n=3). Success of tMSLC was assessed by ad-
herence to plastic (Fig. 1A), the presence of typical MSC surface 
markers (positive for CD105, CD90, and CD72; negative for 
CD45, CD31, and NG2) (Fig. 1B), and tri-lineage differentia-
tion (Fig. 1C). Immunofluorescent labeling of CD105 revealed 
dispersed existence of the tMSLC (Fig. 1D). The tMSLCs were 
successfully isolated from 28 of the 51 specimens (positive 
group) (Table 1), whereas 23 specimens failed to yield tMSLCs 
(negative group) (Table 1). There were no statistically signifi-
cant differences in age, sex, pathological diagnosis, tumor origin, 
IDH-1 mutation, 1p19q codeletion, MGMT promoter methyla-
tion, Ki-67 index, p53, or EGFR mutation status between the 
tMSLC isolation-positive and tMSLC isolation-negative groups 
(Table 1).
Specimen weight distribution
The weights of the glioma specimens ranged from 30 to 2210 
mg. There was no statistically significant difference between 
the mean surgical specimen weights in the tMSLC isolation-
positive and tMSLC isolation-negative groups (469.9±341.9 mg 
vs. 546.7±618.9 mg, respectively, p=0.577) (Fig. 2).
Minimum amount of specimens for tMSLC isolation
Through receiver operating characteristic (ROC) curve, mea-
sured AUC was 0.599 and the corresponding Youden index was 
2.197. This value failed to suggest the optimal cut-off weight of 
fresh specimens for isolating tMSLC (Fig. 3). However, the val-
939
Soon Haeng Kong, et al.
https://doi.org/10.3349/ymj.2021.62.10.936
ue that maximizes sensitivity and specificity was 180 mg, and 
the smallest specimen value in the group in which tMSLC cul-
ture was successful was 100 mg.
Kaplan-Meier survival analysis
The mean follow-up period was 65.8 months with a range of 
1.5 to 79.5 months. The overall survival of the tMSLC-positive 
group was 17.9 months, and that of the tMSLC-negative group 
was 27.8 months. Our analysis revealed that the isolation-posi-
tive group had a lower survival rate compared to the isolation-
negative group (p=0.035) (Fig. 4).
DISCUSSION
The ability to isolate tMSLCs from high-grade gliomas is nega-
tively associated with long-term survival rates.12 We were in-
terested in determining whether certain physical properties of 
tumors, specifically their weight reflecting the amount of spec-
imen, influence the success rate of tMSLC isolation. Therefore, 
we examined the relationship between surgical specimen 
weight and the tMSLC isolation rate from patients with high-
grade glioma, with the presumption that isolation would be 


















































Fig. 1. Representative example of tMSLCs characterization (tMSLC 15-88). (A) The spindle-shaped morphology of the tMSLCs was detected by phase-
contrast microscopy (×100). (B) Flow cytometry was used to detect mesenchymal stem cells surface antigen markers (CD105, CD90, CD73, CD45, CD31, 
and NG2). (C) Differentiation of tMSLCs into osteogenic cells, adipogenic cells, and chondrogenic cells was evaluated by Alizarin Red, Oil Red O, and 
toluidine blue staining, respectively. (D) Immunofluorescent labeling in a glioblastoma specimen showing disperse pattern of tMSLCs. Red fluores-
cence labeling-marked CD105+ cells (tMSLC) were counterstained with DAPI (blue fluorescence) (×200). tMSLCs, tumor mesenchymal stem-like cells.
Fig. 2. Weight distributions of the fresh specimens in the tMSLCs isola-
tion-positive and -negative groups. A comparison of the mean speci-
men weights of the groups (469.9±341.9 mg vs. 546.7±618.9 mg) did not 
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Fig. 3. Receiver-operating characteristic (ROC) curve for the isolation of 
tMSLCs. The area under the curve (AUC) value of 0.599 indicates a poor 
capacity for discrimination, showing that the specimen weight is unre-
lated to the success of tMSLC isolation. tMSLCs, tumor mesenchymal 
stem-like cells.
Fig. 4. Kaplan-Meier curve of the overall survival of the two tMSLCs iso-
lation groups The tMSLC isolation-positive group had a lower survival 
rate than the tMSLC isolation-negative group, as calculated by the log-
rank test (p=0.035). tMSLCs, tumor mesenchymal stem-like cells.
suggest that the success of tMSLC isolation is highly associated 
with poor prognosis and the minimum value for tMSLC isola-
tion. However, the optimal cut-off value did not reach statistical 
significance through the ROC curve. Furthermore, no signifi-
cant differences between the patients’ clinical characteristics, 
such as age, sex, pathological diagnosis, tumor type, and molec-
ular markers, were found between the two groups.
Although several previous studies have isolated MSCs and 
tMSLCs from high-grade gliomas and other tumors,1,3-7,14-18,32 
no ideal sample weight for successful isolation has been es-
tablished to date. It was reported that the ability to isolate tu-
mor spheres from grade IV gliomas was not correlated with the 
specimen weight.13 Another study suggested that the optimal 
volume of tumor specimens for glioma cancer stem cell isola-
tion and culture was at least 0.5 cm3.33 However, this study also 
reported that larger specimens might be better than smaller 
specimens for cell isolation, owing to the differences among 
fresh specimens in cell density, tissue texture, and necrosis sta-
tus. This implies that the technical success rate of tMSLC isola-
tion from larger specimens may be higher than from smaller 
samples, regardless of the actual presence of tMSLCs in the 
sample, leading to a false prediction of longer survival rates in 
patients with small “tMSLC-negative” tumors. Herein, we tried 
to clarify the relationship between the specimen weight and 
the successful isolation of tMSLCs affecting the patients’ prog-
nosis.
The MSC isolation procedure can be difficult to perform, as 
it requires deft technical skills and close attention to detail. 
Therefore, some studies have proposed protocols that are pu-
tatively more effective for MSC isolation,34-37 although they ac-
knowledge that tMSLCs may not be obtained from all fresh 
tumor specimens using these protocols. In our study, tMSLCs 
were obtained from 28 of the 51 (54.9%) WHO grade III/IV gli-
oma specimens, and from 24 of the 39 (61.5%) WHO grade IV 
gliomas under optimal conditions. Due to the technical diffi-
culties associated with tMSLC isolation, researchers may sus-
pect their low success rates. To alleviate some of these concerns, 
we showed that the amount of the specimens is not critical for 
tMSLC isolation. Furthermore, the AUC value of the ROC curve 
(0.599) indicated a poor capacity for discrimination, showing 
that the specimen amount appears to be less related to the 
success of tMSLC isolation. Instead, we suggested the mini-
mum specimen weight (100 mg) for which tMSLC isolation 
was successful, and this value could be useful as a reference 
for future studies on tMSLC. 
Consistent with previous reports, we found that the isola-
tion-positive group had lower patient survival rates compared 
to the isolation-negative group (Fig. 4).12 By dividing the pa-
tients into two groups based on tMSLC isolation, we were able 
to determine whether other factors, such as specimen weight, 
were associated with the success of isolation. However, no dif-
ference was found in any patient characteristics. Based on the 
fact that human MSCs inhibit the immune response by block-
ing allorecognition and interfering with dendritic cell or T-cell 
function,38 we speculate that the poor prognosis of the tMSLC 
isolation-positive group is related to tMSLCs downregulating 
the body’s immune reaction against the tumor, helping the tu-
mor to flourish.
However, the conclusions of this study must be interpreted 
carefully, as this study had several limitations. First, the number 
of specimens used was not enough to obtain conclusive results. 
Since type 2 error cannot be ruled out, a larger study would re-
veal a clearer relationship between the amount of specimen 
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mine a plausible reason for being unable to isolate the tMSLCs. 
While some tumors may be tMSLC-negative, technical difficul-
ties in isolating tMSLCs imply that the false-negative rate is like-
ly high. Third, although all samples were weighed after remov-
ing blood clots and debris as much as possible, it was not 
possible to completely dry up the samples to perform tMSLC 
isolation, which could cause some bias. The present study sug-
gests the minimum weight of specimen for tMSLC isolation, 
which is highly associated with poor prognosis. However, due 
to low AUC value, a successful tMSLC isolation does not de-
pend on the weight of the specimen only, or on other proper-
ties of the tumor. The results of this study will alleviate surgeons’ 
concerns about whether specimen weight impacts the suc-
cessful isolation of tMSLCs. 
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